From the Journals

Transcatheter Arterial Chemoembolization for Rectal Tumors?


 

TOPLINE:

Transcatheter arterial chemoembolization (TACE), a standard treatment for liver metastases from colorectal cancer, shows promise for treating locally advanced rectal tumors.

METHODOLOGY:

  • The combination of neoadjuvant chemoradiotherapy, total mesorectal excision, and postoperative adjuvant chemotherapy is the current standard of care for locally advanced rectal cancer. But with pathological complete response rates of only 10%-15% and more than 30% of patients developing distant metastases within 3 years, outcomes remain suboptimal.
  • Chinese investigators took a step to improve the situation, applying TACE — a standard treatment for colorectal liver metastases — to rectal tumors, dubbing the approach transcatheter rectal arterial chemoembolization (TRACE).
  • As in TACE, TRACE uses precisely injected chemotherapeutic and vaso-occlusive agents to shut down blood flow to tumors, starving them of oxygen and nutrients.
  • The research team tried the approach in 111 patients with stage II or III rectal tumors and performance status scores of 0-1.
  • TRACE was delivered with oxaliplatin and followed by radiotherapy and S1 chemotherapy (tegafur, gimeracil, and potassium oteracil). Total mesorectal excisions were performed 4-8 weeks later, followed by mFOLFOX6 (5-fluorouracil, leucovorin, and oxaliplatin) or CAPOX (oxaliplatin and capecitabine) chemotherapy for 4-6 months.

TAKEAWAY:

  • Overall, 20.7% of patients undergoing TRACE had a pathological complete response, and almost half (48.65%) had a major pathological response.
  • Nearly 62% of patients were disease-free at 5 years, and almost 75% were alive at 5 years.
  • No serious surgical complications occurred, but 21.6% of patients had postoperative complications. Overall, about 26% of patients (29 of 111) had grade 3/4 toxicities.

IN PRACTICE:

“The addition of transcatheter rectal arterial chemoembolisation to the neoadjuvant therapy can improve the pathological remission rate and prognosis in patients with locally advanced rectal cancer, without increasing the incidence of preoperative adverse events and postoperative complications,” the researchers concluded. “Given its promising effectiveness and safe profile, incorporating TRACE into the standard treatment strategy for patients with [locally advanced rectal cancer] should be considered.”

SOURCE:

The work, led by W. Yang of the Army Medical University in Chongqing, China, was published in Clinical Oncology.

LIMITATIONS:

The study was performed at a single center with no control arm in a Chinese population.

DISCLOSURES:

The work was funded by the Third Military Medical University in China. The investigators had no conflicts of interest.

A version of this article appeared on Medscape.com.

Recommended Reading

No Compelling Evidence of Pancreatic Cancer Risk With GLP-1s
Federal Practitioner
Immunotherapy Combo Wins Big on PFS in First-Line Mets CRC
Federal Practitioner
Targeted Colorectal Cancer Combo Improves QoL
Federal Practitioner
The Case for Biomarker Testing in Gastroesophageal Cancer
Federal Practitioner
Bladder Cancer: Is Active Surveillance the Way Forward?
Federal Practitioner
Dana-Farber Moves to Retract, Correct Dozens of Cancer Papers Amid Allegations
Federal Practitioner
Treatment Sequence May Impact Pancreatic Cancer Survival
Federal Practitioner
Do Multivitamin Supplements Lower Mortality Risk in CRC?
Federal Practitioner
Should CRC Surveillance Extend Beyond 5 Years Post Surgery?
Federal Practitioner
Is ChatGPT Reliable for CRC Screening/Surveillance Advice?
Federal Practitioner